In Conversation

What are the main tasks of the LEEM? The LEEM is the only professional organization representing the pharmaceutical industry in France. It includes almost all companies…

July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within…

The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the…

The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the…

What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The…

Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you…

One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two…

You have a wide professional experience that goes from financial adviser to biotechnology entrepreneur, passing through software business and politics. How will all of those different…

Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your…

Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI…

Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for…

The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here